Sorafenib induced acneiform eruptions

A case report

Ommurugan Balaji, D. Amita Priya, Navin Patil

Research output: Contribution to journalArticle

Abstract

Sorafenib an oral tyrosine kinase inhibitor is used in the treatment of hepatocellular carcinoma, renal cell carcinoma, and thyroid cancer. Sorafenib acts by inhibiting various kinases such as tyrosine kinase, rearranged during transfection tyrosine kinase, endothelial growth factor receptor, vascular endothelial growth factor 2 and 3 inhibits angiogenesis, and cell proliferation. Acneiform eruptions are known side effect of epidermal growth factor receptor inhibitors but acneiform eruptions with sorafenib is seldom seen. Hence we report a case of sorafenib - induced acneiform eruptions.

Original languageEnglish
Pages (from-to)6-7
Number of pages2
JournalAsian Journal of Pharmaceutical and Clinical Research
Volume10
Issue number4
DOIs
Publication statusPublished - 01-04-2017

Fingerprint

Acneiform Eruptions
Protein-Tyrosine Kinases
Renal Cell Carcinoma
Vascular Endothelial Growth Factor Receptor
Thyroid Neoplasms
Epidermal Growth Factor Receptor
Vascular Endothelial Growth Factor A
Transfection
Hepatocellular Carcinoma
Phosphotransferases
Cell Proliferation
sorafenib

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

@article{600ac0159e0a4776896ed476b31251a1,
title = "Sorafenib induced acneiform eruptions: A case report",
abstract = "Sorafenib an oral tyrosine kinase inhibitor is used in the treatment of hepatocellular carcinoma, renal cell carcinoma, and thyroid cancer. Sorafenib acts by inhibiting various kinases such as tyrosine kinase, rearranged during transfection tyrosine kinase, endothelial growth factor receptor, vascular endothelial growth factor 2 and 3 inhibits angiogenesis, and cell proliferation. Acneiform eruptions are known side effect of epidermal growth factor receptor inhibitors but acneiform eruptions with sorafenib is seldom seen. Hence we report a case of sorafenib - induced acneiform eruptions.",
author = "Ommurugan Balaji and {Amita Priya}, D. and Navin Patil",
year = "2017",
month = "4",
day = "1",
doi = "10.22159/ajpcr.2017.v10i4.16805",
language = "English",
volume = "10",
pages = "6--7",
journal = "Asian Journal of Pharmaceutical and Clinical Research",
issn = "0974-2441",
publisher = "Innovare Academics Sciences Pvt. Ltd",
number = "4",

}

Sorafenib induced acneiform eruptions : A case report. / Balaji, Ommurugan; Amita Priya, D.; Patil, Navin.

In: Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, No. 4, 01.04.2017, p. 6-7.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sorafenib induced acneiform eruptions

T2 - A case report

AU - Balaji, Ommurugan

AU - Amita Priya, D.

AU - Patil, Navin

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Sorafenib an oral tyrosine kinase inhibitor is used in the treatment of hepatocellular carcinoma, renal cell carcinoma, and thyroid cancer. Sorafenib acts by inhibiting various kinases such as tyrosine kinase, rearranged during transfection tyrosine kinase, endothelial growth factor receptor, vascular endothelial growth factor 2 and 3 inhibits angiogenesis, and cell proliferation. Acneiform eruptions are known side effect of epidermal growth factor receptor inhibitors but acneiform eruptions with sorafenib is seldom seen. Hence we report a case of sorafenib - induced acneiform eruptions.

AB - Sorafenib an oral tyrosine kinase inhibitor is used in the treatment of hepatocellular carcinoma, renal cell carcinoma, and thyroid cancer. Sorafenib acts by inhibiting various kinases such as tyrosine kinase, rearranged during transfection tyrosine kinase, endothelial growth factor receptor, vascular endothelial growth factor 2 and 3 inhibits angiogenesis, and cell proliferation. Acneiform eruptions are known side effect of epidermal growth factor receptor inhibitors but acneiform eruptions with sorafenib is seldom seen. Hence we report a case of sorafenib - induced acneiform eruptions.

UR - http://www.scopus.com/inward/record.url?scp=85017159528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017159528&partnerID=8YFLogxK

U2 - 10.22159/ajpcr.2017.v10i4.16805

DO - 10.22159/ajpcr.2017.v10i4.16805

M3 - Article

VL - 10

SP - 6

EP - 7

JO - Asian Journal of Pharmaceutical and Clinical Research

JF - Asian Journal of Pharmaceutical and Clinical Research

SN - 0974-2441

IS - 4

ER -